The potential benefit of PCSK9 inhibitors for NAFLD patients has been suggested; however, future research should focus on PCSK9 inhibitors and their therapeutic role in PCOS and NAFLD patients. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.